AN2 Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

ANTX$4.00+1.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and per share amounts)

	March 31,	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$19,985	$21,351
Short-term investments	47,075	62,267
Prepaid expenses and other current assets	2,499	2,644
Total current assets	69,559	86,262
Long-term investments	11,480	5,021
Other assets, long-term	304	804
Total assets	$81,343	$92,087
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,073	$3,317
Accrued compensation	529	1,676
Accrued liabilities	4,043	4,454
Other current liabilities	369	791
Total liabilities	8,014	10,238
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024	—	—
Common stock, $0.00001 par value; 500,000,000 shares authorized at March 31, 2025 and December 31, 2024; 30,141,517 and 29,919,634 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively	—	—
Additional paid-in capital	289,706	287,594
Accumulated other comprehensive gain	48	31
Accumulated deficit	(216,425)	(205,776)
Total stockholders’ equity	73,329	81,849
Total liabilities and stockholders’ equity	$81,343	$92,087

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.